| Literature DB >> 25339943 |
Masaru Usui1, Yukie Nanbu1, Kentaro Oka2, Motomichi Takahashi3, Takashi Inamatsu4, Tetsuo Asai5, Shigeru Kamiya6, Yutaka Tamura1.
Abstract
Clostridium difficile colonization in pig intestine has been a public health concern. We analyzed C. difficile prevalence among piglets in Japan to clarify their origin and extent of the associated risk by using molecular and microbiological methods for both swine and human clinical isolates and foreign isolates. C. difficile was isolated from 120 neonatal piglet fecal samples. Toxin gene profile, antimicrobial susceptibilities, PCR ribotype, and multiple-locus variable-number tandem-repeat analysis (MLVA) type of swine isolates were determined and compared with those of human clinical and foreign isolates. One-hundred C. difficile strains were isolated from 69 (57.5%) samples, and 61 isolates (61%) were toxin gene-positive. Some isolates were resistant to antimicrobials, contributing to antibiotic-associated diarrhea by C. difficile. These results suggest that C. difficile, prevalent among Japanese pigs, is a potential risk for antibiotic-associated diarrhea. Furthermore, PCR ribotype 078 (12 isolates), which has been linked to multiple outbreaks worldwide, was the third-most frequently isolated of the 14 PCR ribotypes identified. Moreover, MLVA revealed that all 12 PCR ribotype 078 isolates were genetically related to European PCR ribotype 078 strains found in both humans and pigs. To date, in Japan, many breeding pigs have been imported from European countries. The genetic relatedness of C. difficile isolates of Japanese swine origin to those of European origin suggests that they were introduced into Japan via imported pigs.Entities:
Keywords: Clostridium difficile; MLVA; PCR ribotype 078; antimicrobial resistance; piglets
Year: 2014 PMID: 25339943 PMCID: PMC4189341 DOI: 10.3389/fmicb.2014.00513
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers used in the present study.
| Gene target | Primer name | Primer sequence (5′-3′) | Amplicon size (bp) | Reference |
|---|---|---|---|---|
| 16S rDNA | CIDIF-F | CTTGAATATCAAAGGTGAGCCA | 1085 | |
| CIDIF-R | CTACAATCCGAACTGAGAGTA | |||
| tcdA-F3345 | GCATGATAAGGCAACTTCAGTGGTA | 629 | ||
| tcdA-R3969 | AGTTCCTCCTGCTCCATCAAATG | |||
| tcdB-F5670 | CCAAARTGGAGTGTTACAAACAGGTG | 410 | ||
| tcdB-R6079A | GCATTTCTCCATTCTCAGCAAAGTA | |||
| tcdB-R6079B | GCATTTCTCCGTTTTCAGCAAAGTA | |||
| cdtA-F739A | GGGAAGCACTATATTAAAGCAGAAGC | 221 | ||
| cdtA-F739B | GGGAAACATTATATTAAAGCAGAAGC | |||
| cdtA-R958 | CTGGGTTAGGATTATTTACTGGACCA | |||
| cdtB-F617 | TTGACCCAAAGTTGATGTCTGATTG | 262 | ||
| cdtB-R878 | CGGATCTCTTGCTTCAGTCTTTATAG | |||
| NK9 | CCACCAGCTGCAGCCATA | 2355a | ||
| NKV011 | TTTTGATCCTATAGAATCTAACTTAGTAAC | |||
Isolation and toxin gene profile of Clostridium difficile from Japanese piglets.
| Farm | Location of prefecture | Samples | No. of positive samples | No. of isolates | Toxin A+B+ | Toxin A-B-CDT- | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDT+ | CDT- | |||||||||||||
| A | Hokkaido | 10 | 9 | 11 | 0 | 10 | 1 | |||||||
| B | Hokkaido | 10 | 7 | 8 | 0 | 8 | 0 | |||||||
| C | Hokkaido | 10 | 8 | 10 | 10 | 0 | 0 | |||||||
| D | Hokkaido | 10 | 7 | 13 | 0 | 0 | 13 | |||||||
| E | Hokkaido | 10 | 9 | 18 | 0 | 17 | 1 | |||||||
| F | Miyagi | 10 | 0 | 0 | 0 | 0 | 0 | |||||||
| G | Miyagi | 10 | 7 | 10 | 5 | 0 | 5 | |||||||
| H | Yamagata | 10 | 3 | 3 | 0 | 0 | 3 | |||||||
| I | Fukushima | 10 | 5 | 7 | 0 | 0 | 7 | |||||||
| J | Tochigi | 10 | 4 | 4 | 4 | 0 | 0 | |||||||
| K | Chiba | 10 | 7 | 9 | 6 | 0 | 3 | |||||||
| L | Gifu | 10 | 3 | 7 | 1 | 0 | 6 | |||||||
| Sub Total | 26 | 35 | ||||||||||||
| Total | 120 | 69 (57.5%) | 100 | 61 (61.0%) | 39 (39.0%) | |||||||||
Antimicrobial susceptibility of Clostridium difficile piglet isolates and human clinical isolates.
| Piglet | Humanc | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/mL) | MIC (μg/mL) | No. of resistant isolates ( | MIC (μg/mL) | No. of resistant isolates ( | |||||
| Antimicrobials | Break point | 50% | 90% | Range | 50% | 90% | Range | ||
| Vancomycin | ≥32a | 1 | 2 | 1–4 | 0 | 0.5 | 1 | 0.06–2 | 0 |
| Metronidazole | ≥32b | 0.5 | 8 | 0.125–8 | 0 | 0.25 | 0.25 | <0.06–0.25 | 0 |
| Clindamycin | ≥8b | 8 | 256 | 0.25–>256 | 59 (59.0%) | 256 | >256 | 0.125–>256 | 64 (87.7%) |
| Ceftriaxone | ≥64b | 16 | 32 | 2–>256 | 6 (6.0%) | 256 | 256 | 0.125–>256 | 62 (84.9%) |
| Erythromycin | ≥8a | 2 | >256 | 1–>256 | 46 (46.0%) | >256 | >256 | <0.125–>256 | 61 (83.6%) |
| Ciprofloxacin | ≥4a | 8 | 8 | 0.5–128 | 75 (75.0%) | 64 | 64 | 0.125–64 | 68 (93.2%) |
Relationship between the PCR ribotype and the toxin gene profile.
| PCR Ribotypes | No. of isolates | Toxin A+B+ | Toxin A-B-CDT- | |
| CDT+ | CDT- | |||
| P1 | 34 | 8 | 9 | 17 |
| P2 | 20 | 0 | 0 | 20 |
| P3 | 12 | 12 | 0 | 0 |
| P4 | 9 | 0 | 9 | 0 |
| P5 | 6 | 0 | 6 | 0 |
| P6 | 5 | 5 | 0 | 0 |
| P7 | 3 | 0 | 3 | 0 |
| P8 | 3 | 0 | 3 | 0 |
| P9 | 2 | 2 | 0 | 0 |
| P10 | 2 | 0 | 2 | 0 |
| P11 | 1 | 1 | 0 | 0 |
| P12 | 1 | 0 | 1 | 0 |
| P13 | 1 | 0 | 1 | 0 |
| P14 | 1 | 0 | 1 | 0 |
For each strain, the results of the optimized MLVA for each of the 7 loci.
| Isolate No. | Farm | MLVA result (No. of tandem repeats for indicated locus) | ||||||
|---|---|---|---|---|---|---|---|---|
| A6cd | B7cd | C6cd | E7cd | F3cd | G8cd | H9cd | ||
| 1 | E | NA | 22 | 37 | 8 | 4 | 10 | 2 |
| 2 | E | NA | 22 | 37 | 8 | 4 | 10 | 2 |
| 3 | E | NA | 22 | 37 | 8 | 4 | 10 | 2 |
| 4 | F | NA | 8 | 36 | 9 | 4 | 4 | 2 |
| 5 | J | NA | 22 | 34 | 8 | 4 | 11 | 2 |
| 6 | J | NA | 21 | 36 | 8 | 4 | 11 | 2 |
| 7 | J | NA | 22 | 36 | 8 | 4 | 11 | 2 |
| 8 | J | NA | 22 | 35 | 8 | 4 | 11 | 2 |
| 9 | J | NA | 18 | 36 | 8 | 4 | 11 | 2 |
| 10 | J | NA | 22 | 35 | 8 | 4 | 11 | 2 |
| 11 | J | NA | 22 | 36 | 8 | 4 | 11 | 2 |
| 12 | J | NA | 21 | 36 | 8 | 4 | 11 | 2 |
| 12ENa | NA | 25 | 33 | 8 | 4 | 12 | 2 | |